Barclays lowered the firm’s price target on UnitedHealth (UNH) to $603 from $604 and keeps an Overweight rating on the shares. The firm says that following a “chaotic first week” of Q3 earnings that featured material medical loss ratio misses and negative outlook surprises, it evaluated the resets and read-throughs from UnitedHealth’s and Elevance Health’s earnings reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Election 2024: Where To Put Your Money Ahead of the Vote
- UnitedHealth incentivized doctors to pile diagnoses onto MA patients, STAT says
- UnitedHealth price target raised to $609 from $601 at TD Cowen
- Evolent weakness linked to elevated Medicaid MLRs at peers, says Stephens
- UnitedHealth downgraded to Hold from Buy at HSBC (earlier)